JP2007506681A5 - - Google Patents

Download PDF

Info

Publication number
JP2007506681A5
JP2007506681A5 JP2006527166A JP2006527166A JP2007506681A5 JP 2007506681 A5 JP2007506681 A5 JP 2007506681A5 JP 2006527166 A JP2006527166 A JP 2006527166A JP 2006527166 A JP2006527166 A JP 2006527166A JP 2007506681 A5 JP2007506681 A5 JP 2007506681A5
Authority
JP
Japan
Prior art keywords
antibody
use according
medicament
asthma
daclizumab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006527166A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007506681A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/031640 external-priority patent/WO2005030252A1/en
Publication of JP2007506681A publication Critical patent/JP2007506681A/ja
Publication of JP2007506681A5 publication Critical patent/JP2007506681A5/ja
Pending legal-status Critical Current

Links

JP2006527166A 2003-09-23 2004-09-21 抗ｉｌ−２受容体抗体による呼吸器疾患の治療 Pending JP2007506681A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50588303P 2003-09-23 2003-09-23
US55297404P 2004-03-12 2004-03-12
PCT/US2004/031640 WO2005030252A1 (en) 2003-09-23 2004-09-21 Treatment of respiratory diseases with anti-il-2 receptor antibodies

Publications (2)

Publication Number Publication Date
JP2007506681A JP2007506681A (ja) 2007-03-22
JP2007506681A5 true JP2007506681A5 (OSRAM) 2007-11-08

Family

ID=34396276

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006527166A Pending JP2007506681A (ja) 2003-09-23 2004-09-21 抗ｉｌ−２受容体抗体による呼吸器疾患の治療

Country Status (8)

Country Link
US (1) US20050089517A1 (OSRAM)
EP (1) EP1675615A1 (OSRAM)
JP (1) JP2007506681A (OSRAM)
AU (1) AU2004275860A1 (OSRAM)
BR (1) BRPI0414688A (OSRAM)
CA (1) CA2538737A1 (OSRAM)
RU (1) RU2006113701A (OSRAM)
WO (1) WO2005030252A1 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3087991A1 (en) 2003-11-08 2016-11-02 Prothera Biologics Composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
EP2291654B1 (en) 2008-05-28 2018-04-11 Prothera Biologics, Inc. Preparation and composition of inter-alpha inhibitor proteins from blood
CA2743768A1 (en) * 2008-12-10 2010-06-17 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Inhibition of inter-alpha trypsin inhibitor for the treatment of airway disease
EP2710384B1 (en) 2011-05-12 2017-11-08 Temple University - Of The Commonwealth System of Higher Education Diagnosis and treatment of copd
US9572872B2 (en) 2012-09-09 2017-02-21 Prothera Biologics, Inc. Treatment of disease using inter-alpha inhibitor proteins
EP3512539A4 (en) 2016-09-13 2020-07-29 Prothera Biologics, Inc. METHODS FOR TREATING LUNG DISEASE USING INTER-ALPHA INHIBITOR PROTEINS
US10472405B2 (en) 2016-12-13 2019-11-12 Delinia, Inc. Multivalent regulatory T cell modulators
CA3061164A1 (en) 2017-04-25 2018-11-01 Prothera Biologics, Inc. Methods for quantifying inter-alpha inhibitor proteins
US12478739B2 (en) * 2018-12-29 2025-11-25 Kaleo, Inc. Devices and methods for delivery of substances within a prefilled syringe
CA3155137A1 (en) * 2019-10-04 2021-04-08 R.P. Scherer Technologies, Llc Anti-cd25 antibody-maytansine conjugates and methods of use thereof
US12268847B1 (en) 2021-02-10 2025-04-08 Kaleo, Inc. Devices and methods for delivery of substances within a medicament container
CN118370816A (zh) * 2024-03-22 2024-07-23 中日友好医院(中日友好临床医学研究所) Il-2/抗il-2抗体免疫复合物的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4473493A (en) * 1981-04-29 1984-09-25 Immunex Corporation Hybridoma antibody which inhibits interleukin 2 activity
US4411993A (en) * 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4845198A (en) * 1984-05-21 1989-07-04 Immunex Corporation Hybridoma antibody which binds IL-2 receptor
US5336489A (en) * 1985-09-05 1994-08-09 The Beth Israel Hospital Association Treatment of allograft rejection with IL-2 receptor-specific cytotoxins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1992008474A2 (en) * 1990-11-20 1992-05-29 The National Heart & Lung Institute Treatment of lung diseases
WO1996032151A1 (en) * 1995-04-14 1996-10-17 Glaxo Wellcome Inc. Metered dose inhaler for fluticasone propionate
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
DE69937057T2 (de) * 1998-07-27 2008-05-29 Novartis Ag Verwendung von basiliximab zur behandlung von rheumatoider arthritis und hauterkrankungen
CN1296386C (zh) * 2001-04-06 2007-01-24 布里斯托尔大学 Cd25结合分子在类固醇耐受型患者中的用途
BRPI0316282B8 (pt) * 2002-11-15 2021-05-25 Genmab As anticorpo humano isolado monoclonal, composição, imunoconjugado, molécula biespecífica ou multiespecífica, método e conjunto de diagnóstico para detectar a presença de antígeno cd25 ou uma célula que expressa cd25, e, vetor de expressão

Similar Documents

Publication Publication Date Title
KR102390714B1 (ko) 벤랄리주맙을 이용하여 천식의 악화 속도를 감소시키는 방법
JP2015527364A5 (OSRAM)
JP2017507139A5 (OSRAM)
RU2015109716A (ru) Способы лечения или предотвращения астмы посредством введения антагониста il-4r
JP2007506681A5 (OSRAM)
JP2007522229A5 (OSRAM)
JP2009511480A5 (OSRAM)
JP2006527193A5 (OSRAM)
CA2569077A1 (en) Combinations comprising antimuscarinic agents and corticosteroids
CN107073114B (zh) 使用瑞利珠单抗治疗中度到重度嗜酸细胞性哮喘
IL271132B1 (en) Dry powder aclidinium salt pharmaceutical composition for treatment of copd
RU2006113701A (ru) Лечение респираторных заболеваний антителами против рецептора il-2
JP2019528316A5 (OSRAM)
CA2568571A1 (en) Combinations comprising antimuscarinic agents and corticosteroids
JP2008110991A (ja) 処置方法
JP2015511625A5 (OSRAM)
KR102337601B1 (ko) 벤랄리주맙을 이용하여 천식 증상을 개선시키는 방법
JP2013525310A5 (OSRAM)
JP2014012683A5 (OSRAM)
TWI870471B (zh) 全身性硬化症治療用醫藥組合物
Kuhn Immunoglobulin E blockade in the treatment of asthma
Masekela et al. Asthma treatment in children: A pragmatic approach
Smith Fixed-combination inhalers for asthma and chronic obstructive pulmonary disease
EP4267184B1 (en) Interleukin 5 binding protein dosage regimen
US20250042985A1 (en) Interleukin 5 binding protein dosage regimen for use in treating polyangiitis, hypereosinophilic syndrome, chronic rhinosinusitis with nasal polyps (crswnp), or chronic rhinosinusitis without nasal polyps (crssnp)